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Background: Obesity is characterized by impaired fat oxidation, and, therefore, the development of therapeutics
designed to enhance fat oxidation for treating obesity is a growing focus in drug discovery. Evaluating such
agents, however, is challenging in a clinical setting; requisite overnight fasting prior to a study visit increases
whole body fat oxidation in lean, healthy subjects, making incremental increases potentially difficult to detect.
Methods: We recruited 16 lean/overweight participants and eight obese participants to evaluate novel methodology
designed to optimally detect increases in fat oxidation. Carbohydrate intake was increased for three days leading up to
the overnight test visit and evaluated as either a standalone strategy to suppress overnight fasting-related increases in
fat oxidation or was combined with overnight administration of IV glucose in a subset of lean/overweight subjects.
Indirect calorimetry was performed the following morning to examine the degree to which these interventions
were able to diminish fasting related increases in fat oxidation. Fat oxidation was then subsequently stimulated
by challenging patients with a lipid infusion to determine the importance of the preceding interventions on the
ability to detect statistically significant increases in fat oxidation.
Discussion: In lean/overweight subjects, suppression of fasting-related increases in fat oxidation via increased
dietary carbohydrate intake was not necessary to detect subsequent meaningful increases in fat oxidation rates
following Intralipid infusion; however, a statistically significant decrease in respiratory quotient following Intralipid
infusion could only be observed when the infusion was preceded with high carbohydrate dietary intake. Glucose
infusion, which further suppressed fasting-related fat oxidation, in turn led to more dramatic increases in
Intralipid-driven fat oxidation. Both lean/overweight and obese subjects could demonstrate statistically significant
increases in fat oxidation following Intralipid infusion, a finding which supports the inclusion of obese subjects in
similar future clinical studies. Lastly, serum levels of β-hydroxybutyrate correlated strongly with fat oxidation rates,
as well as respiratory quotient, suggesting potential as a surrogate biomarker of fax oxidation. Taken together,
we demonstrate the utility of novel methodology to facilitate measuring changes in fat oxidation in lean/
overweight and obese human volunteers in a clinical setting similar to that needed to test drugs designed
to increase fat oxidation.
Keywords: Fat oxidation, Intralipid, Respiratory quotient, Hood calorimetry, Obese, Metabolic flexibility* Correspondence: Stephanie.Parsons@flhosp.org
1Translational Research Institute for Metabolism and Diabetes, Florida
Hospital, 301 E. Princeton Street, Orlando, FL 32804, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Parsons et al. Translational Medicine Communications  (2016) 1:6 Page 2 of 13Background
There is an ever growing need for new and innovative
approaches for the treatment of obesity, and obesity-
related diseases (such as type 2 diabetes). Recent evi-
dence suggests that impaired fat oxidation may be both
a risk factor for the development of obesity as well as a
barrier to effective weight loss [1–7]. Biological pathways
that act to positively regulate fat oxidation and energy
expenditure are, therefore, desirable targets for the
design of therapeutic agents to combat obesity. Vital
to the development of such compounds or biological
agents, is the ability to test the efficacy of such agents
in a clinical setting.
Increasing the flux of lipid into oxidative pathways is an
attractive means to reverse metabolic diseases. First, re-
duced metabolic flexibility, a common hallmark of obesity,
involves both impaired post-absorptive fat oxidation and
decreased insulin stimulated glucose oxidation [8]. Toxic
lipid intermediates are thought to produce insulin resist-
ance at the cellular level [9–11]. Increasing fatty acid oxi-
dation (FAOx) would presumably lead to a reduction of
these intermediates and promote insulin action. Second,
increased FAOx might create a negative energy balance.
States of increased lipid supply and oxidation are associ-
ated with increased energy expenditure (EE) [12]. In-
creases in EE might offset the metabolic adaptation that
occurs with weight loss [13, 14]. Lastly, small changes in
energy metabolism, over a long time frame and without
compensatory changes in energy intake, can lead to an
overall decrease in fat mass. This is thought to explain
how increased habitual physical activity leads to better
weight maintenance [15].
Early phase metabolic clinical studies typically center
on safety and proof of concept, and often enlist lean
healthy volunteers. The overnight fast that routinely pre-
cedes each study visit can make it challenging to detect
changes in fat oxidation in this population. Healthy
volunteers are generally highly metabolically flexible and
will readily switch from carbohydrate to fat oxidation
during an overnight fast [7, 8]. Hence, under fasted con-
ditions, these subjects already demonstrate higher than
normal rates of fat oxidation, and any further stimula-
tion of fat oxidation by a pharmacologic agent may be
difficult to measure.
The purpose of this study was to evaluate novel ap-
proaches to mitigate fasting-related increases in fat oxida-
tion in order to augment subsequent Intralipid-mediated
increases in fat oxidation. These approaches were evalu-
ated in both healthy lean or overweight and obese subjects
in a setting typical of early phase clinical trials. In lean/
overweight individuals, we evaluated two approaches, a
high carbohydrate diet with or without IV glucose, in
order to determine if a nutrition-based strategy would
be sufficient to adequately suppress fasting inducedincreases in fat oxidation, or if IV glucose throughout
the overnight hours would be necessary to achieve this
goal. We also examined the utility of this strategy in
healthy obese individuals, the target population for fat
oxidation-enhancing therapeutics. Additionally, we ex-
amined the potential utility of serum βOHB as a sensi-
tive biomarker for evaluating changes in whole body fat
oxidation. β − hydroxybutyrate (βOHB), a metabolite pro-
duced by liver mitochondria during the oxidation of fatty
acids, is upregulated during fasting or hypoglycemic con-
ditions, as well as during infusion of lipid emulsions, such
as Intralipid [16, 17]. Showing this metabolite to be a
sensitive and robust biomarker of changes in fat oxida-
tion could have implications for its inclusion in future
clinical studies.Methods
Ethical approval and screening
The study protocol was approved by the Florida Hospital
Institutional Review Board and was carried out in ac-
cordance with the Declaration of Helsinki. Before taking
part in the study, all subjects were evaluated for eligibil-
ity. All participants provided their written consent to
take part in the study and were aware that they were free
to withdraw from the experiments at any point. Proce-
dures during the screening visit included the informed
consent process, measurement of height and weight,
Body Mass Index (BMI) calculation, waist measurement,
vital signs (heart rate, blood pressure), electrocardiogram
(ECG), medical history and physical, report of concomi-
tant medications, lab work (complete blood count, com-
prehensive metabolic profile [consisting of tests for
albumin, alkaline phosphatase, alanine aminotransferase,
aspartate aminotransferase, blood urea nitrogen, calcium,
chloride, carbon dioxide, creatinine, glucose, potassium,
sodium, total bilirubin, total protein], CK, TSH, CRP, urin-
alysis, lipid profile [LDL, HDL, triglycerides], and serum
beta hCG [for women of childbearing potential]).Subjects
Twenty-four healthy men and women between the ages
of 19 and 54 years of age took part in this study. Partic-
ipants included 16 lean or overweight subjects (BMI ≥
18– < 30) and eight obese subjects (BMI 30–35, inclu-
sive). Female subjects were of non-childbearing potential.
All were in good health and without evidence or history of
clinically significant hematological, renal, endocrine, pul-
monary, gastrointestinal, cardiovascular, hepatic, psychi-
atric, neurologic, allergic (including drug allergies, but
excluding untreated, asymptomatic, seasonal allergies
at time of dosing), muscle disease, diabetes, or severe
uncontrolled hypertension.
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During a baseline visit occurring within two weeks
prior to the overnight test visit, a frequently-sampled
intravenous glucose tolerance test (FSIGTT) was per-
formed following an overnight fast. For three days prior
to the overnight test visit, all subjects were instructed
to consume a diet high in carbohydrates. Ahead of this,
subjects received nutritional counsel from nursing staff
and were given examples of high carbohydrate foods
(e.g., pasta, rice, potatoes) and were shown how to deter-
mine carbohydrate content from nutrition labels. Partici-
pants were instructed simply to consume greater than
150 g carbohydrates per day. No other standardization of
dietary intake was imposed. For the overnight test visit,
subjects were admitted to the research unit in the late
afternoon. At approximately 18:00 subjects consumed a
final high carbohydrate evening meal (either chicken par-
mesan with pasta and a side salad, or spaghetti with meat-
balls and side salad, and a side of bread), followed by a
snack (package of graham crackers and cup of 2 % milk)
at 22:00.
Lean/overweight healthy subjects were randomized
into Group 1 or Group 2.
Group 1: Lean/overweight subjects receiving overnight
saline infusion (designated LS)
Group 2: Lean/overweight subjects receiving overnight
glucose infusion (designated LG)
Group 3: Consisted of obese subjects receiving
overnight saline (designated OS)
Intravenous glucose (10 % Dextrose in Water, or D10W)
or normal saline infused was infused at a rate of 125 ml/h
from 22:00 until approximately 11:45 the following
morning (see Fig. 1). This rate was determined as fol-
lows: The energy requirements (kcal) were determined
based on the needs of a 70 kg male consuming a stand-
ard American diet consisting of 35 % fat, 15 % protein,
50 % carbohydrates. We then determined the amount
of carbohydrate needed to completely replace carbohy-
drate oxidation of this prototypical subject at rest. Those
requirements informed the glucose infusion rate (4 kcal/g
glucose). This rate was intended to provide sufficientFig. 1 Overview of Study Activities. Overview of timing of measurements acalories to support REE (less the obligatory protein oxi-
dation rate), increase insulin (and therefore suppress
lipolysis), facilitate lipid storage through the increase in
circulating insulin, and decrease lipid supply and oxida-
tion. Additionally, we anticipated a reduction in FFA
levels during the glucose infusion.
Immediately after stopping the glucose or saline infusion,
Intralipid 20 % infusion (Manufactured by Fresenius Kabi,
Uppsala, Sweden, for Baxter Healthcare Corporation,
Deerfield, IL http://www.accessdata.fda.gov/drugsatfda_docs/
label/2007/017643s072,018449s039lbl.pdf) was started at a
rate of 1.5 ml/min. The duration of Intralipid infusion
was 3 h.
Selected unblinded study staff verified, via two-nurse
validation, that the test visit IV infusion (saline vs glucose)
was appropriately indicated and administered according
to the assigned randomization treatment. Any unblinded
source documentation was secured in manila envelopes,
which were then, distributed and managed only by un-
blinded study staff. Study blind was also maintained to the
participant and all other study staff by obscuring the infu-
sion bag and the content labeling.Frequently sampled intravenous glucose tolerance test
Bilateral antecubital IV lines were inserted, and 300 mg/kg
glucose was injected at time = 0 min, followed by collection
of blood samples (4 cc) at 1–2 min intervals until time =
20 min. At time = 20 min, a bolus of insulin (0.03 U/kg or
0.015 U/kg if the subject was considered lean and likely to
be very insulin sensitive) was given via the IV line, and
frequent sampling resumed for another 10 min. For the re-
mainder of the test (180 min), blood samples were collected
every 10–20 min. Each blood sample was analyzed for glu-
cose, insulin, and free fatty acid (FFA). These data were
then submitted for calculation of the insulin sensitivity
index (SI) and glucose effectiveness (SG) using the Minimal
Model method of Bergman [18]. The minimal model ana-
lysis was accomplished using a program developed for
the personal computer (MINMOD-Millennium, copy-
right R. Bergman), currently run in the PI’s laboratory.
The FSIGTT was then performed with the addition of
exogenous insulin injection.nd sample collection that occurred within this study
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Blood samples were collected as depicted in Fig. 1. Dur-
ing the overnight test visit, blood samples were collected
hourly (starting at 07:00) for measurement of glucose
(YSI 2300 Stat Plus, Yellow Springs, OH), insulin (Meso
Scale Discovery, Human Insulin, Rockville, MD), free
fatty acids (WAKO NEFA - HR(2), Wako Life Sciences,
Inc., Mountain View, CA), and triglycerides (Wako L-
Type Triglyceride M, Wako Diagnostics, Richmond,
VA) – all measured at The Translational Research
Institute for Metabolism and Diabetes (TRI-MD).
Samples were also collected for measurement of serum
β-hydroxybutyrate (βOHB). βOHB was quantitated by
GC/MS (ThermoFisher Trace GC Ultra/DSQ II single
quadrupole mass spectrometer) in the Metabolomics
Core at the Sanford Burnham Prebys Medical Discovery
Institute. Calibration standards (1–1000 μM) were pre-
pared in water and spiked with 13C 3-βOHB (500 μM)
as an internal standard. βOHB was extracted from
plasma using a series of extraction and derivatization
steps to form the corresponding trimethylsilyl derivative.
Detection of the derivatized β-OHB was achieved by
single ion monitoring after GC separation [19]. βOHB
levels were measured at two timepoints during the glu-
cose or saline infusion period (09:30 and 11:30), as well
as at the end of the Intralipid infusion period (15:00).
DEXA
Body composition was measured using a GE Lunar iDXA,
running enCORE software version 13.3 (GE Medical Sys-
tems, Bucks, UK). All DEXA scans were analyzed in the
Imaging Core using enCORE software to determine lean
soft tissue mass (g), fat mass, including visceral adipose
tissue, (g), and bone mass (g) of standard body regions, in-
cluding leg, arm and trunk compositions. Test-retest CVs
average 0.7 % across a range of body composition.
Indirect calorimetry
Baseline visit (During FSIGTT)
Following IV line insertions and a 45 min rest period, in-
direct calorimetry was performed for 20 min each (once
fasting, and once post glucose and insulin administration
starting at 40 min post glucose injection) during the
Baseline 1 FSIGTT. Respiratory quotient was measured
using a MAX II Metabolic cart (AEI Technologies,
Naperville, IL). The instrument was calibrated before
each subject with standardized gases containing 5 %
CO2 and 95 % O2. Subjects were instructed to lie in a
Semi-Fowler’s position (supine position with the head of
the bed positioned at approximately 30–45°) and remain
motionless and awake during these periods. A transpar-
ent plastic hood connected to the device was placed over
the head of the subject. Calculations of O2 consumption
(VO2) and CO2 production (VCO2) were made fromcontinuous measurements of CO2 and O2 concentra-
tions in inspired and expired air diluted in a constant air
flow (~40 L/min). The respiratory quotient (RQ) is de-
fined by the ratio VCO2/VO2 and is an index of sub-
strate use by the body; the relative volumes depend on
the fuel source being metabolized. Respiratory coefficients
range from about 1.0 (pure carbohydrate oxidation) to
about 0.7 (pure fat oxidation). RQ was determined during
an initial study baseline visit (within a 2 week window of
the subsequent overnight test visit, no restrictions on
macronutrient composition of the free-living diet). Prior
to admission, dietary carbohydrate was increased as de-
scribed in the Experimental Protocol. RQ was again
measured during the test visit, following overnight infusion
of either saline (LS, OS) or glucose (LG). Upon waking,
the infusion continued, and RQ values were measured
in hourly intervals.
Test visit
Following awakening and measurement of supine vitals,
indirect calorimetry was performed for 30 min following
a 30 min rest period, with the first 10 min of data dis-
carded to ensure accuracy of the resting measurement.
Indirect calorimetry was performed every hour there-
after. The rates of lipid oxidation were calculated as de-
scribed by Elia and Livesey [20].
Urine
An overnight urine specimen was collected from bed-
time to 06:30 for the measurement of urinary nitrogen
and creatinine to calculate protein oxidation.
Fat oxidation rate was calculated based on the equations
derived by Jequier et al. [21]: 1.689 × VO2 – 1.689 ×
VCO2 – 0.324 × Protein Oxidation, where protein oxida-
tion is calculated from Urinary Nitrogen (UN). Urine col-
lection was not performed during the baseline visit and
therefore the UN values from the following visit were used
as an estimate of protein oxidation.
Statistical analyses
All data was analyzed either with Statistical Analysis Sys-
tem (SAS) or GraphPad Prism 6. Prior to performing
data analysis, standard data screenings and audits were
applied. These included screening demographic data for
data entry errors, assessing the pattern of missing data,
checking the distribution of each endpoints, and checking
for outliers. For the description of baseline characteristics,
continuous data were presented as the mean +/− standard
error and categorical data were summarized as frequen-
cies and percentage by treatment groups. A two sample
t-test was applied to check the difference of each char-
acteristic between lean and obese subjects. The only
exception was that the non-parametric Chi-square test
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two groups.
The potential effects of treatment, time (pre-/post-
Intralipid), and interaction were investigated using re-
peated measures ANOVA using SAS mixed procedure
followed by post-hoc pairwise comparison (with stepdown
Bonferroni or Tukey-Kramer correction). Pre-Intralipid
data points were considered as baseline for each subject. If
there were no statistical difference between these baseline
data points, the pre-Intralipid values were expressed as
the average of these points. For serum βOHB values,
logarithmic transformation was performed as the data
were skewed; subsequently, correlations were performed.
The results with a P value ≤ 0.05 were considered statisti-
cally significant.
Results
The Lean, Saline (LS) study population was comprised
of five lean or overweight males and three lean or over-
weight females, Lean, Glucose (LG) group of six lean or
overweight males and two lean or overweight females,
and the Obese, Saline (OS) group of four obese malesTable 1 Anthropometric and baseline laboratory values of the study
Lean
Saline
Age (yr) 35.7 ± 3.9
Sex (M/F) 5/3
Height (cm) 177.1 ± 5.7
Weight (kg) 81.8 ± 4.9
BMI (kg/m2) 25.7 ± 1.0
Waist circumference (cm) 87.1 ± 3.7
Glucose (mg/dL) 85.3 ± 1.9
Insulin (ulU/mL) 61.7 ± 12.9
Free Fatty Acids (mmol/L) 0.57 ± 0.06
Triglycerides (mg/dL) 90.0 ± 10.6
Thyroid-Stimulating Hormone (mlu/L) 2.04 + 0.38
Creatine Phosphokinase (lu/L) 89.8 ± 14.2
DEXA
Total body mass (kg) 81.5 ± 6.8
Total lean mass (kg) 52.3 ± 5.2
Total fat mass (kg) 26.1 ± 2.9
Visceral adipose tissue mass (g) 742.50 ± 173.87
% Body fat 32.3 ± 3.1
FSIGTT
Glucose effectiveness (SG) 0.0201 ± 0.0031
Insulin sensitivity (SI) 4.9 ± 0.9
Acute insulin response to glucose (AIRg) 385.1 ± 110.8
Data is represented as Mean ± SEM; Bold: P (two-sample t-test) < 0.05
aChi squared testand four obese females. As stated, the Lean groups (LS,
LG) are comprised of both lean and overweight subjects
but are denoted as “L” for simplicity. Table 1 depicts the
anthropometric and baseline laboratory values of the
study populations. Values of all lean/overweight partici-
pants (n = 16) are used for comparison with the Obese
group. The average age of the OS group was 43.7 years,
significantly older than the average age of the Lean
population. In addition, weight, BMI, total body mass,
fat mass, % body mass, and glucose values were all sig-
nificantly greater in the Obese group. There were no
significant differences in any of the values in Table 1
between the LS and LG groups.
Insulin sensitivity and insulin secretion were deter-
mined during the first baseline visit using an FSIGTT.
There were no significant differences between the Lean
and Obese cohorts or between the LS and LG groups.
Glucose infusion reduces overnight fasting induced
increases in fat oxidation
Lean/overweight participants consuming an ad libitum
diet exhibited an overnight fasted RQ of 0.861 ± 0.01. Inpopulation at screening
Obese p-value
Glucose Saline Lean vs. obese
32.0 ± 2.2 43.7 ± 3.8 0.0272
6/2 4/4 0.2059a
182.2 ± 1.8 170.8 ± 4.5 0.1064
75.9 ± 3.4 95.3 ± 3.9 0.0001
22.7 ± 1.2 32.3 ± 0.5 <.0001
83.3 ± 4.5 106.3 ± 4.5 0.0005
84.3 ± 1.5 99.1 ± 2.4 <.0001
57.4 ± 7.9 52.9 ± 8.9 0.5917
0.26 ± 0.03 0.43 ± 0.04 0.7864
118.7 ± 30.5 128.0 ± 15.6 0.3619
1.69 ± 0.21 1.79 ± 0.26 0.8308
102.6 ± 19.2 123.8 ± 19.8 0.2145
76.5 ± 4.7 96.5 ± 5.7 0.0219
52.8 ± 3.0 54.7 ± 4.8 0.6907
20.7 ± 2.8 38.6 ± 1.8 0.0001
518.63 ± 222.32 1262.63 ± 167.13 0.012
26.7 ± 2.5 40.7 ± 2.1 0.003
0.0205 ± 0.0043 0.0165 ± 0.0021 0.344
5.4 ± 0.8 3.8 ± 1.1 0.2569
279.0 ± 32.6 497.4 ± 177.4 0.3883
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all higher average fasting baseline RQ value (0.895 ±
0.026), but this difference was not found to be significant
(Fig. 2a). All participants received a glucose challenge as
part of a frequently sampled intravenous glucose toler-
ance test (FSIGTT). Results from this test determined
that measures of glucose effectiveness, insulin sensitivity,
and acute insulin response to glucose were similar be-
tween lean/overweight and obese participants (Table 1).
Both lean/overweight and obese participants showedFig. 2 Effect of Diet and Overnight Glucose Infusion on Fasting
Respiratory Quotient Values. a RQ values obtained during the
FSIGTT procedure, fasting versus post-glucose and insulin infusion.
**Denotes significant difference within group between fasting RQ
and RQ measured post-glucose and insulin administration between
the same group, **P = 0.008 obese and lean. b Comparison of fasting
RQ obtained prior to the FSIGTT procedure (baseline study visit), to
RQ measured during the Pre-Intralipid phase of the test visit. #Denotes
significant difference in LG group with respect to the LS group,
P = 0.03. &Denotes significant difference in LG group with respect
to the OS group, P = 0.04. ***Denotes significant difference within
LG group for RQ measured after high carbohydrate diet + overnight
saline or glucose with respect to fasting RQ measured during ad
libitum dietary intake, P = 0.0009similar upward shifts in their RQ values as measured
between 40 and 60 min following glucose infusion, indi-
cative of increased glucose oxidation in both groups.
These increases were significant post- vs. pre-glucose
challenge (Lean 0.920 ± 0.017, P = 0.008; Obese 0.981 ±
0.042, P = 0.008) (Fig. 2a).
As described in Methods, the test visit was preceded
by three days of high carbohydrate dietary intake, cul-
minating with a high carbohydrate meal and snack just
prior to initiation of the overnight test visit infusion
protocol (no further meals were consumed until the
conclusion of the test visit the following day, ~3 p.m.).
At approximately 23:00 on the night of the test visit, an
antecubital IV was inserted, and IV glucose (LG) or
normal saline (LS, OS) was infused overnight. Upon
waking, the infusion continued, and RQ values were
measured in hourly intervals. For the LS group, when
comparing participants’ average morning (08:00–11:00)
RQ measurement to their fasted RQ measurement ob-
tained immediately prior to the FSIGTT procedure, we
observed that short term consumption of a high carbo-
hydrate diet alone did not significantly increase RQ
values, despite a slight observed increase (0.859 ± 0.013
vs 0.892 ± 0.002; Fig. 2b). For the OS group, which dem-
onstrated a higher baseline RQ under fasting conditions,
no change in RQ could be observed with a high carbo-
hydrate diet (0.895 ± 0.026 vs 0.895 ± 0.005). However,
overnight infusion of glucose plus the high carbohydrate
diet (LG) resulted in a significantly higher average RQ
value as compared to fasting RQ in the same group mea-
sured just prior to FSIGTT procedure (Ad Lib Diet,
0.868 ± 0.016 vs. 0.969 ± 0.008; P = 0.009) (Fig. 2b). Aver-
age morning RQ values following overnight infusion for
the LG group were also significantly higher than both
the LS and OS groups (P = 0.03 vs. LS, P = 0.04 vs. OS).
These results indicate that in lean/overweight, healthy
individuals, short term high carbohydrate dietary intake
alone has no significant effect on RQ values following an
overnight fast, but overnight glucose administration in
combination with short term high carbohydrate results
in significantly greater glucose oxidation as compared to
overnight saline administration.
Glucose and Intralipid infusion with or without dietary
manipulation effects plasma metabolic parameters
As with RQ, plasma levels of glucose, insulin, FFAs and tri-
glycerides were measured at regular hourly intervals on the
morning of the test visit, beginning at 08:00. It should be
noted that there were no significant differences in any of
these measurements at any of the timepoints analyzed.
Therefore, for the purposes of comparison with post-
Intralipid levels, average values of these morning timepoints
were used. Morning (also referred to as “pre-Intralipid”)
glucose levels were significantly elevated in participants in
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(Fig. 3a). Participants in the LG group demonstrated the
highest levels of blood glucose among all of the groups
(100.048 ± 2.835 mg/dL vs. 83.956 ± 2.204 mg/dL, LS, P <
0.0001 and vs. 90.885 ± 2.771 mg/dL, OS, P < 0.0001). Intra-
lipid administration commenced at approximately 12:00.
Following Intralipid administration, glucose levels in the LS
group showed a slight downward trend toward the end
of the Intralipid infusion period (Fig. 3a). In contrast,
participants in the LG group, showed a dramatic de-
crease in blood glucose within the first 30 min of Intra-
lipid infusion (from 100.048 ± 2.835 mg/dL to 81.071 ±
2.896 mg/dL, P < 0.0001, Fig. 3a). Changes in glucose
levels in participants in the OS group were similar to
those of the LS group (Fig. 3a).
Insulin levels showed similar patterns to glucose levels
throughout the pre- and post-Intralipid infusion periods
(Fig. 3b). Despite pre-Intralipid insulin levels appearing
higher in participants in the OS group (5.751 ± 1.090Fig. 3 Pre- and Post-Intralipid Glucose, Insulin, Triglycerides, and Free Fatty Ac
of saline or glucose and glucose levels following Intralipid infusion. b Average
insulin levels following Intralipid infusion. c Average baseline FFA levels m
Intralipid infusion. d Average baseline triglycerides levels measured during inf
infusion. $Denotes significant differences at the indicated timepoint in the LS
the indicated timepoint in the LG groups with respect to the LS group. &Den
with respect to the OS group. *Denotes significant differences within group a
Pre-Intralipid/Baseline measure of the same group. Arrow indicates that, for th
11:45. Note: For all symbols: *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001uUI/mL) relative to those in the LS group (3.127 ± 0.236
uUI/mL), however, this difference was not significant
(P = 0.145). Participants in the LG group, though, did
demonstrate significantly higher insulin levels relative
to the other groups (7.247 ± 1.899 uUI/mL vs. LS, P <
0.0001 and vs. OS, P < 0.0001, Fig. 3b). Following Intrali-
pid administration, insulin levels in participants in both
the LS group and the OS group remained constant. Partic-
ipants in the LG group, however, demonstrated dramatic
significant decreases in insulin levels within the first
30 min following the switch from glucose to Intralipid
infusion (3.454 ± 0.707 uUI/mL, P = 0.03), with levels
remaining similar thereafter (Fig. 3b).
FFAs measured in the LG group were significantly lower
relative to participants in the LS and OS groups (0.056 ±
0.005 mEq/L vs. 0.356 ± 0.063 mEq/L, LS, P < 0.0001, and
vs. 0.269 ± 0.033 mEq/L, OS, P = 0.03, Fig. 3c). No signifi-
cant difference in FFA levels were detected between LS
and OS groups. During Intralipid administration, FFAids Values. a Average baseline glucose levels measured during infusion
baseline insulin levels measured during infusion of saline or glucose and
easured during infusion of saline or glucose and FFA levels following
usion of saline or glucose and triglycerides levels following Intralipid
group with respect to the OS group. #Denotes significant differences at
otes significant differences at the indicated timepoint in the LG groups
t the indicated Post-Intralipid timepoint with respect to the average
e LG subjects, the 10 % IV glucose infusion was stopped at approximately
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levels ceasing to be significantly different from the LS and
OS groups by 90 min post-Intralipid infusion (Fig. 3c).
No significant differences in triglyceride levels were
observed prior to or following Intralipid infusion be-
tween any of the treatment groups (Fig. 3d). All groups
demonstrated similar significant increases in triglyceride
levels following infusion of Intralipid.
Mitigation of fasting-related increases in fat oxidation
enable better detection of changes in fat oxidation
following intralipid infusion
As mentioned, RQ was measured hourly throughout the
morning and afternoon hours of the test visit. Within
groups, RQ measurements were not significantly differ-
ent throughout the morning hours (08:00–11:00) as sa-
line or glucose infusion continued (Fig. 4a). It should be
noted that in the OS group only, RQ measured at theFig. 4 Pre- and Post-Intralipid Respiratory Quotient Values and Fat
Oxidation Rates. a RQ values measured during the Pre-Intralipid phase
of the test visit. b Fat oxidation rates measured under fasting conditions,
with (CHO Diet) or without (Ad Lib Diet) high carbohydrate dietary
intake, ±Glucose, and following Intralipid infusion. *Denotes significant
difference within group, Post-Intralipid measure with respect to the
average Pre-Intralipid measure. $Denotes significant difference in Post-
Intralipid measure with respect to the Ad Lib Diet measure. #Denotes
significant difference in Pre-Intralipid measure with respect to the Ad
Lib Diet measure. Note: For all symbols: *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001,
****P≤ 0.000107:00 timepoint was significantly higher as compared to
two of the other four a.m timepoints (data not shown).
For this reason, average morning baseline values were
determined for all groups using the 08:00–11:00 time-
points only. As described earlier, lean/overweight partici-
pants receiving IV glucose (LG) had significantly higher
mean baseline RQ values than those receiving saline
(Fig. 2b). Following the switch to Intralipid infusion, RQ
values decreased sharply and significantly for all groups
relative to Pre-Intralipid (Baseline) values (Additional
file 1: Figure S1A). Notably, by 14:00, there ceased to
be a difference between RQ values in the LG vs LS
groups, but for the OS group this difference persisted
at 15:00 (Additional file 1: Figure S1A).
In addition to respiratory quotient values, fat oxidation
rates were calculated as described in Methods. Rates
from participants during the pre-glucose infusion period
that preceded the FSIGTT procedure (Ad Lib Diet) were
compared to rates from those same participants ob-
tained during the morning of the test visit, prior to the
switch to Intralipid (CHO Diet, Pre-Intralipid). For the
LS and OS groups, this comparison permits the examin-
ation of the high carbohydrate diet alone on lipid oxida-
tion rates. We observed an average decrease in lipid
oxidation rate in the LS group of 19 % with high carbo-
hydrate intake, which was not significant (Fig. 4b). Like-
wise, there was no effect of the high carbohydrate diet
on fat oxidation rates in the OS group (Fig. 4b). The
addition of the glucose infusion to the high carbohydrate
intake in the LG group, however, effectively reduced lipid
oxidation as evidenced by an average of 81 % (#P = 0.038).
Following 2.5 h of Intralipid infusion, rates of fat oxidation
increased significantly in all groups (Fig. 4b). Rates in
the LS group increased by an average of +106 % and in
the OS group by an average of +145 %, relative to pre-
Intralipid values, while the average change in the LG
group was +648 % following the switch to Intralipid
(Fig. 4b). Notably, the high carbohydrate diet was not
necessary to detect subsequent significant increases in
fat oxidation rates after Intralipid infusion in either the
LS or OS groups (post-Intralipid vs ad lib diet, fasted,
$P = 0.034, LS, and $$$$P = 0.0001, OS, Fig. 4b).
When doing a similar comparison for RQ values mea-
sured prior to the baseline FSIGTT (Ad Lib Diet) to
those measured following Intralipid infusion (Post-Intra-
lipid), a ΔRQ of −3.78 % and −0.96 % were observed for
the lean/overweight groups (LS and LG, respectively,
Table 2). For the OS group, which had a higher baseline
(Ad Lib Diet) RQ than the lean/overweight groups, this
decrease was significant. In contrast to what was ob-
served for average fat oxidation rates in the LS group,
however, the change in RQ between the ad lib diet and
post-Intralipid timepoint was not significant. Furthermore,
although the minor increase in RQ with consumption of a
Table 2 Effect of nutrient intake and glucose/intralipid infusion
on respiratory quotient
Mean percent change in RQ




Lean, Saline −3.8 ± 2.0 −7.9 ± 1.3
Lean, Glucose −0.96 ± 2.8 −11.3 ± 2.0
Obese, Saline −10.43 ± 3.3 −10.49 ± 1.6
RQ respiratory quotient; Values are Mean ± SEM, Bold denotes P ≤ 0.05
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(Additional file 1: Figure S1B), this increase did, how-
ever, facilitate a statistically significant ΔRQ (−7.89 %,
Table 2) between the CHO Diet and Post-Intralipid
states in the LS group. Combining glucose infusion
with the high carbohydrate diet resulted in an even
greater ΔRQ of −11.44 % in the LG group (P < 0.0001;
Table 2). In obese subjects, the post-Intralipid ΔRQ wasFig. 5 Pre- and Post-Intralipid Levels of Serum β-Hydroxybutyrate. a Serum
test visit. b Correlation between average Pre-Intralipid serum βOHB levels a
Pre-Intralipid serum βOHB levels and average Pre-Intralipid fat oxidation rat
phase of the test visit and Post-Intralipid βOHB serum levels. **Denotes sig
respect to the average Pre-Intralipid/Baseline measure for the same group
and LG group with respect to the Post-Intralipid timepoint (P = 0.007)significant with or without high carbohydrate dietary in-
take (−10.43 % compared to ad libitum diet fasting condi-
tions and −10.49 % compared to fasting conditions post
high carbohydrate consumption, Table 2). Graphs depict-
ing the effect of each experimental condition on RQ in
each group are presented in Additional file 1: Figure S1A,
S1B, and S1C.
Serum levels of 3-hydroxybutyrate negatively correlate
with RQ and positively correlate with fat oxidation
Participants in the LS group demonstrated the highest Pre-
Intralipid concentrations of βOHB (78.74 ± 26.34 μM),
while participants in the OS group exhibited intermediate
levels (23.70 ± 5.97 μM), and participants in the LG group
showed the lowest levels (5.19 ± 1.92 μM) (Fig. 5a). We
investigated the potential significance of differences in pre-
Intralipid βOHB levels among our groups by analyzing
combined βOHB levels from both pre-Intralipid timepoints.levels of βOHB levels as measured during Pre-Intralipid phase of the
nd average Pre-Intralipid RQ values. c Correlation between average
es. d Average βOHB serum levels measured during the Pre-Intralipid
nificant difference within group at the Post-Intralipid timepoint with
(P = 0.005, both). ##Denotes significance difference between LS group
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between any of the groups. However, analysis of average
βOHB readings at the pre-Intralipid timepoints in all
groups and their corresponding average RQ values or
average fat oxidation rates revealed a significant nega-
tive correlation (P = 0.0075) between RQ and βOHB
and a significant positive correlation (R = 0.0129) be-
tween fat oxidation rate and βOHB was found (Fig. 5b
and c, respectively). It is important to note that, for this
analysis, log transformation of the βOHB data was per-
formed in order to conform the skewness of the data. It
should also be noted that correlation of pre- and post-
Intralipid RQ or fat oxidation rates and βOHB could
not be determined due to skewing of the pre-Intralipid
βOHB data.
Following Intralipid infusion, increases in βOHB were
observed in all three groups relative to pre-Intralipid
levels. These increases were significant for the LS (P =
0.005) and OS (P = 0.005) groups (Fig. 5d). Post-Intralipid
levels of βOHB in the LS group remained significantly
higher than LG group (##P = 0.007, Fig. 5d) and trended
higher (P = 0.08) as compared to the OS group.
Discussion
Increased de novo lipogenesis and impaired fatty acid
oxidation appear to be key in the development of obesity
and insulin resistance. Therefore, enzymes in these path-
ways have generated keen interest as targets for therapeutic
intervention. Such therapies, however, can encounter sig-
nificant challenges when it comes to clinical testing. One
of these challenges centers around the fact that fasting is a
routine requirement of volunteers prior to a study visit.
However, fasting alone is sufficient to increase fat oxidation
in healthy subjects. This increase could very conceivably
diminish the subsequent effects of the pharmacotherapy
and make further increases related to the intervention
less likely to be observed. Furthermore, detection of drug-
related increases in fat oxidation may require increased
substrate availability. Our protocol takes into account
these important considerations, and, as we have shown,
demonstrates that, in a clinical setting under conditions
typical of a phase 1 test visit, 1) changes in fat oxidation in
human subjects can be measured in a sensitive and robust
manner, and 2) statistically meaningful increases in fat
oxidation can be observed.
Fundamental to our protocol design was the suppres-
sion of fasting-induced increased fat oxidation through a
nutrition-based approach, either alone or in combination
with intravenous infusion of glucose. We found that in-
creasing the carbohydrate intake of both lean/overweight
and obese participants through consumption of a high
carbohydrate diet for a period of three days neither led
to significantly higher fasting RQ values nor significantly
decreased lipid oxidation, although minor shifts in theLS group could be observed. However, infusion of glu-
cose in combination with the high carbohydrate diet
during the overnight hours of the test visit, did result in
dramatic significant decreases in lipid oxidation and in-
creased RQ.
Following overnight infusion of either saline or glu-
cose, a switch to Intralipid infusion was initiated as a
means to increase lipid availability and drive fat oxida-
tion, and all groups demonstrated significant increases
in fat oxidation in response to this lipid challenge. To
better determine how essential the high carbohydrate
diet, with or without glucose infusion, was to this obser-
vation, a comparison of participants’ fasting RQ values
and lipid oxidation rates (obtained during a baseline
study visit, prior the FSIGTT procedure, ad libitum diet-
ary intake), and these measures post-Intralipid infusion
(test visit) were carried out. With regard to RQ, for lean/
overweight participants, the high carbohydrate diet alone
proved necessary and sufficient. The modest increases in
RQ owing to the carbohydrate intake were adequate to
enable subsequent detection of statistically significant
decreases in RQ in response to Intralipid infusion. How-
ever, when evaluating lipid oxidation rates, this was not
found to be the case. In fact, significant increases in fat
oxidation (LS group) with Intralipid could be detected
without any dietary changes or IV glucose. However, the
changes were less striking as compared to the observed
with the glucose infusion. Taken together, these findings
suggest that in future clinical studies, for lean or over-
weight subjects it may be prudent to implement mea-
sures to inhibit fasting-induced increases in fat oxidation
subsequent to clinical testing of therapeutic agents to
enhance fat oxidation. Furthermore, while not tested
here, infusion of glucose without the accompanying high
carbohydrate diet could be ideal approach to doing this
when precise standardization of pre-testing nutrient in-
take proves impractical.
The high carbohydrate diet had no effect on lipid oxi-
dation or RQ in obese subjects and was not necessary to
observe statistically significant increases in fat oxidation,
although the high carbohydrate diet did further increase
the significance of ΔRQ pre- versus post-Intralipid. It
has been reported previously that fasting RQ is elevated
in at the whole body level in obese adolescents [22] and
in subjects with a family history of type 2 diabetes [23].
While we consistently observed elevated fasting RQ/
lower rates of fat oxidation under ad libitum conditions
in our obese participants relative to the lean/overweight
participants, these differences did not prove to be signifi-
cant. Perhaps the most noteworthy observation with this
subject group, however, is their preservation of their meta-
bolic flexibility to lipid and ability to adapt fat utilization
to availability. This is important as these individuals repre-
sent the target population for pharmacotherapies designed
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dence that a pharmacodynamic response to therapeutics
designed to enhance fat oxidation could be detected in the
healthy obese population and greatly strengthens the
rationale for their inclusion in early clinical studies.
Finally, we found that accompanying the decrease in
RQ and increase in lipid oxidation with Intralipid infu-
sion was corresponding increase in serum levels of
βOHB. Increased circulating levels of ketones are a nor-
mal response to increased lipid flux to the liver from
the adipose tissue; fatty acids are transformed in the
mitochondria of liver and kidney cells to ketone units,
including βOHB, which then circulate back into the
bloodstream. Significant increases in βOHB in response
to Intralipid infusion in both the LS and OS groups
were observed. Increases were also observed in the LG
group, but the increase was not statistically significant,
presumably due in part to a lag in βOHB production
resultant from the prior glucose infusion. Furthermore,
before infusion of Intralipid was even initiated, βOHB
levels were clearly found to have a significant negative
correlation with RQ and significant positive correlation
with lipid oxidation. Serum βOHB may, therefore, have
utility in the clinic as a secondary biomarker for meas-
uring fat oxidation.
While the protocol presented here highlights several
important considerations for the design of future clinical
studies to measure changes in fat oxidation, our ap-
proach is not without certain limitations. For example,
here we employ Intralipid infusion to drive increased
lipid oxidation, perhaps making it most relevant with re-
spect to testing of therapeutics that raise fatty acids to
drive fat oxidation. To that point, however, the ability of
indirect calorimetry to sensitively measure changes in
relative macronutrient oxidation and energy expenditure
is well-established, and our protocol serves simply to
create an optimal experimental environment that poten-
tiates the ability to reveal significant increases in fatty
acid oxidation in those subjects that already have a high
capacity for fatty acid oxidation. Unfortunately, we have
neither a pharmacological agent available to serve as a
positive control in our study, nor has a clinically mean-
ingful change in fatty acid oxidation yet been defined, so
it is not possible yet to put the changes in lipid oxidation
that we see with our model into this context. “Real-world”
testing of our model and assessment of the benefits of in-
creased fatty acid oxidation will depend the development
of these pharmacological agents and will permit us to fully
test the metabolic flexibility hypothesis.
Another shortcoming of our study is limited data to
support the observation that βOHB could be robust and
sensitive biomarker of fat oxidation. While it is clear that
dramatic increases in βOHB are associated with increases
in fat oxidation (in general, a 10 % reduction in RQ isassociated with about an 800 % increase in βOHB), statis-
tical analysis of the pre- and post-Intralipid correlation of
RQ and βOHB was not possible due to the skewness of
the pre-Intralipid βOHB data; whether there is a signifi-
cant correlation will, therefore, require further efforts to
establish. Toward this end, the inclusion of graded Intrali-
pid infusions may be helpful in better refining the rela-
tionships between lipid supply, oxidation, and biomarkers
such as βOHB or acylcarnitines. It also merits consider-
ation that biomarkers of increased oxidation driven by
lipid excess may differ from biomarkers that relate to the
activation of enzymes that consume fatty acids or from
biomarkers that relate to increasing demand for substrate
(such as uncoupling). This is an important potential dis-
tinction for future investigation.
In conclusion, while diet and behavior modifications will
continue to be an important focus with regard to the
treatment and management of obesity, the achievement of
long-term, clinically relevant weight loss will likely be
achieved only through the development of novel and in-
novative therapies, such as those that promote increased
fat oxidation. The critical evaluation of such therapies will
require equally innovative approaches in the clinic. Here
we have demonstrated the utility of a novel approach de-
signed to enable statistically significant changes in fatty
acid oxidation to be measured in a clinical setting.
Conclusion
The pursuit of new anti-obesity pharmacotherapies is in-
creasingly focused on strategies to target pathways im-
portant for the regulation of energy balance. Of
particular interest is the modulation of enzymes that
play a key role in mitochondrial β-oxidation. As these
agents ascend into the clinic for evaluation, demonstra-
tion of their ability to promote fat oxidation will be cru-
cial and likely require preemptive measures to diminish
the effect of other factors, such as fasting or diet, that
impact fat oxidation. The protocol described herein
demonstrates the utility of these measures and may
serve as a paradigm for such studies moving forward.
Additional file
Additional file 1: Figure S1. Pre- and Post-Intralipid Respiratory Quotient
Values. A. Average RQ values measured during the Pre-Intralipid/Baseline
phase of the test visit and post-Intralipid RQ values. #Denotes significant
difference in LG group Pre-Intralipid/Baseline measure with respect to the
LS group. &Denotes significant difference in LG group Pre-Intralipid/Baseline
measure with respect to the OS group. *Denotes significant difference
within group, Post-Intralipid measure with respect to the average Pre-
Intralipid/Baseline measure. B. RQ measured under fasting conditions,
with (CHO Diet) or without (Ad Lib Diet) high carbohydrate dietary
intake, ±Glucose, and following Intralipid infusion. *Denotes significant
difference within group, Post-Intralipid measure with respect to the
average Pre-Intralipid measure. $Denotes significant difference in Post-
Intralipid measure with respect to the Ad Lib Diet measure. #Denotes
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Lib Diet measure. C. Comparison of fasting RQ values (“Between Day”)
and RQ values obtained during the saline or glucose infusion phase of the test
visit (“Within Day”) to post-Intralipid RQ values. *Denotes significant difference
within group, Post-Intralipid measure with respect to the Pre-Intralipid/Baseline
measure. Note: For all symbols: *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001.
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